HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

HuM195-gelonin

an immunotoxin used in bone marrow purging

Also Known As:

HuM195-rGel

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	McGrath, Melissa S: 1 article (01/2003)
2.	Philips, Mark R: 1 article (01/2003)
3.	Rosenblum, Michael G: 1 article (01/2003)
4.	Scheinberg, David A: 1 article (01/2003)

Related Diseases

1.	Myeloid Leukemia (Leukemia, Myelocytic) 02/01/1996 - "In the current study, a recombinant humanized immunotoxin, HuM195-rGel, was evaluated in vivo in a nude mouse model of human myeloid leukemias. "
2.	Leukemia 01/01/2003 - "K562 leukemia cells retrovirally infected to overexpress P-gp are also resistant to HuM195-gelonin. " 02/01/1996 - "These data show that HuM195-rGel can target leukemia cells in vivo and can result in pronounced anti-leukemic effects." 02/01/1996 - "HuM195-rGel was found to target leukemia cells rapidly in vivo and was subsequently internalized into the cells. "
3.	Neoplasms (Cancer) 02/01/1996 - "HuM195-rGel demonstrated significant tumor suppressive activity in this model. " 02/01/1996 - "While all mice treated with either saline, rGel alone, or HuM195 plus unconjugated rGel (at 10 or 14 days after transplantation) had rapid tumor growth or early deaths, 50% of mice treated with HuM195-rGel failed to develop leukemic tumors for 5 months and the 50% had significantly retarded tumor growth after treatment with HuM195-rGel. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	Dihydrotachysterol (AT 10)
3.	lintuzumab

Related Therapies and Procedures

1.	Transplantation
2.	Aftercare (After-Treatment)